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Introduction
Vogt–Koyanagi–Harada (VKH) disease is a systemic disorder
with typical bilateral granulomatous panuveitis and variable
degrees of systemic features, including meningismus, vitiligo,
poliosis, and dysacusis. The exact pathogenesis remains un-
known, and a theory of autoimmune response against certain
antigenic component of melanocytes has been suggested [1].
Diagnosis is mainly based on clinical findings. Revised diag-
nostic criteria for VKH disease stressed the importance of the
presence of bilateral uveitis [2]. Most patients do present with
bilateral ocular involvement, where onset in the second eye
might show 2 to 3 weeks of delay than the first eye. However,
several cases of unilateral disease have also been reported
after long-term follow-up [3]. Nowadays, the mainstay of
treatment would be high dose systemic corticosteroid, al-
though steroid-sparing agents should be considered in patients
unable to tolerate steroid or in those who have developed
steroid dependence [4].
Case report
A 49-year-old gentleman first presented to our ophthalmol-
ogy clinic with 1 month history of left eye pain, redness, and
photophobia in August 2006. He was previously an intrave-
nous drug user. His ocular symptoms did not respond to
topical antibiotics prescribed by general practitioners. No
rheumatological, neurological, auricular, or cutaneous fea-
tures were noted. Neither did he have any preceding history
of ocular trauma or surgery. Slit lamp examination of the left
eye revealed grade 2 anterior chamber and vitreous inflam-
mation, according to the Standardization of Uveitis Nomen-
clature classification. Fundoscopy of the left eye showed
multiple pockets of serosanguineous detachment at the pos-
terior pole and perivascular arcade areas with underlying
choroidal inflammatory foci evident, in keeping with diffuse
choroiditis (Fig. 1). A disc swelling and early peripapillary
nerve fiber layer edema were noted as well (Fig. 1). Find-
ings in the right eye were within normal limits (Fig. 2).
Serum anti-HCV was positive. Liver function was normal.
Serum antibody titres for HBV, HIV, and Treponema pal-
lidum were negative. Mantoux test was unremarkable and
both Tspot/Quantiferon tests were negative. Anti-nuclear
antibody was elevated to 80 (speckled pattern, normal <40).
Oral prednisolone (1 mg/kg/day) and topical pred forte
eye drop were started after discussion with hepatologists.
Both were gradually tapered over a period of 13 months.
Sunset-glow fundus was noted in the left eye 5 months after
onset. Right eye examination findings were within normal
limits at that juncture.
Initial HCV RNA titre was 3.45×105 IU/ml. A 24-week
course of antiviral therapy (Ribavirin and peginterferon alfa-
2A) was given between December 2007 and June 2008.
Posttreatment HCV RNA titre was undetectable, indicating
eradication.
Shortly after the antiviral therapy, the patient presented
with a decrease in vision in the right eye in July 2008 (i.e.,
2 years after the first onset). Fundoscopic exam revealed right
eye diffuse choroiditis and exudative retinal detachment. The
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left eye showed a similar sunset-glow fundus as in the previ-
ous review without any signs of active inflammation. Fluo-
rescein angiography showed multifocal of pinpoint leakage
over right eye. A cerebrospinal fluid study found no pleocy-
tosis or presence of malignant cells. A second course of oral
prednisolone (1 mg/kg/day) and topical steroid was prescribed
and tapered off over 5 months. Unfortunately, a repeated HCV
RNA titre during that period was 8.27×105 IU/ml, indicating
a relapse of hepatitis C. In view of the relapsing VKH disease,
hepatologists decided to withhold any further antiviral therapy
and would continue regular monitoring of liver enzymes level
and ultrasonography.
The patient developed a relapse by presenting with pan-
uveitis in the form of vitritis and anterior uveitis in February
2009. The result of a left fundoscopic exam found sunset-
glow changes but no active inflammation. He was resumed
on oral prednisolone (1 mg/kg/day) and topical steroid, with
a prolonged treatment course lasting 30 months. Difficult
tapering with frequent flare-ups of the right eye uveitis was
noted. Furthermore, the right eye developed a complication
by the formation of choroidal neovascularization (Fig. 3) for
which photodynamic therapy was given. Systemic steroid
was finally stopped in September 2011.
The patient remained stable without active ocular inflam-
mation while he was put on topical pred forte. His latest
visual acuity was 12/200 in the right eye and 20/40 in the
left eye. No systemic features developed all along.
Discussion
The revised diagnostic criteria for VKH disease includes:
(1) no history of penetrating ocular trauma or surgery pre-
ceding the onset of uveitis; (2) no evidence suggestive of
other ocular disease; (3) bilateral ocular involvement with
diffuse choroiditis at early stage or ocular depigmentation at
late stage of the disease; (4) neurological or auditory
manifestations, e.g., meningismus and tinnitus; and (5)
integumentory findings, e.g., alopecia, poliosis, and vitili-
go [2]. Our patient fulfilled the criteria for probable VKH
disease with isolated ocular involvement. No systemic
manifestations were identified even after 5 years of
follow-up. It was interesting to note that our patient had
2 years of delay in his second eye with demonstrable
signs of VKH disease, whereas majority of patients only
showed a few weeks of delay. Both eyes had sunset-glow
changes at the end of the follow-up, which was consistent
with the diagnosis of VKH disease.
Concomitant hepatitis C and steroid dependance raised
challenges for management. In general, for patients who are
intolerable to systemic steroid or develop steroid depen-
dance, immunomodulatory agents, such as methotrexate,
cyclosporine, and azathioprine, could be considered. How-
ever, with the presence of hepatitis C, the choice of immu-
nosuppressants became markedly limited in view of
potential flare-up of hepatitis and hepatotoxicity. Our patient
showed a fluctuating clinical course despite prolonged use
of high dose prednisolone. At our latest review, his disease
activity had been controlled with topical steroid. In case of
further flare-ups, sub-tenon steroid injection could also be
considered for his isolated ocular disease. There were sev-
eral case reports of VKH-like disease after administration of
Fig. 1 Left fundus showed multiple pockets of serosanguineous de-
tachment, underlying choroidal inflammatory foci, and a disc swelling
on initial presentation
Fig. 2 Normal right fundus on initial presentation
Fig. 3 Right fundus with features of choroidal neovascularization
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interferon alpha in patients with hepatitis C [5–7]. The exact
mechanism was unknown but a T cell-mediated immune
response was suspected. It would be important to closely
monitor his ocular signs and symptoms in case of further
treatment with interferon alpha in the future.
The clinical and laboratory findings of the patient were
characteristic of a probable VKH disease except for the
initial unilateral involvement for 2 years. Steroid depen-
dence and concomitant hepatitis C raised challenges to
clinicians in management. Alternatives to systemic immu-
nosuppressants could be considered. Despite being a rare
variant, it is important for ophthalmologists to recognize a
unilateral presentation of VKH disease.
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